Benign Prostatic Hyperplasia – Pipeline Review, H2 2016, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape
Pune, Maharashtra -- (SBWIRE) -- 01/31/2017 -- Benign Prostatic Hyperplasia Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Benign Prostatic Hyperplasia therapeutics industry report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.
Browse more detail information about Benign Prostatic Hyperplasia market report at: http://www.absolutereports.com/benign-prostatic-hyperplasia-pipeline-review-h2-2016-10435026
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key players in Benign Prostatic Hyperplasia – Pipeline Review, H2 2016:
- Addex Therapeutics Ltd
- AndroScience Corporation
- Aphios Corporation
- BCWorld Pharm Co. Ltd.
- Biolab Farmaceutica Ltda
- Chong Kun Dang Pharmaceutical Corp.
- Dongkook Pharmaceutical Co., Ltd.
- Hanmi Pharmaceuticals, Co. Ltd.
- Health Ever Bio-Tech Co., Ltd.
- Jeil Pharmaceutical Co., Ltd.
- Kaken Pharmaceutical Co., Ltd.
Get a PDF Sample of Benign Prostatic Hyperplasia Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435026
Drug Profiles of Included in Benign Prostatic Hyperplasia Therapeutics Development Market Report
(dutasteride + tadalafil)
(solifenacin succinate + tamsulosin hydrochloride)
(tadalafil + tamsulosin hydrochloride)
And other drug profiles
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10435026
Key Topics Covered:
1.Introduction
2.Benign Prostatic Hyperplasia Overview
3.Benign Prostatic Hyperplasia Therapeutics Development
4.Pipeline Products for Benign Prostatic Hyperplasia - Overview
5.Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis
6.Benign Prostatic Hyperplasia - Therapeutics under Development by Companies
7.Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes
8.Benign Prostatic Hyperplasia Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Benign Prostatic Hyperplasia - Products under Development by Companies
13.Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes
14.Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
15.Benign Prostatic Hyperplasia Drug Profiles
16.Benign Prostatic Hyperplasia Dormant Projects
17.Benign Prostatic Hyperplasia Discontinued Products
18.Benign Prostatic Hyperplasia Featured News & Press Releases
Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692
May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
And Continue…
Get Discount on Benign Prostatic Hyperplasia Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435026
List of Figures
- Number of Products under Development for Benign Prostatic Hyperplasia, H2 2016
- Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2